Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

依立卢 - NMPA Drug Approval Details

Approvals/NMPA/Fasudil Hydrochloride Injection

Approved

化学药品

Fasudil Hydrochloride Injection

ASAHI KASEI PHARMA CORPORATION🇨🇳 National Medical Products Administration

Approval Date: Mar 19, 2025
Approval ID: 8jU2FftLfiP
Company: ASAHI KASEI PHARMA CORPORATION
Type: 化学药品

Approval Details

Approval Id: 8jU2FftLfiP
Approval Number: 国药准字HJ20150252
Generic Name: 盐酸法舒地尔注射液
Generic Name En: Fasudil Hydrochloride Injection
Trade Name: 依立卢
Drug Type: 化学药品
Dosage Form: 注射剂
Strength: 2ml:30mg
Reg Date: 2025-03-19
Expired Date: 2030-03-18
Company Name: ASAHI KASEI PHARMA CORPORATION
Production Company Address: 爱知县三好市福田町池田61番地
Company Detail Path: /organization/asahi-kasei-pharma-corporation

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Mar 19, 2025

Approval ID

8jU2FftLfiP

Type

化学药品

Back to NMPA Approvals